GlassScriptPhysician profile
Mehran Nowfar-Rad
NPI 1912979048
$1,628.97
in general payments reported to CMS, 2019-2025
21 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $117 · 2022: $146 · 2023: $832 · 2024: $292 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $313.88 | 2022-2025 | |
| Amgen INC. | $274.36 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $236.14 | 2022-2024 | Taltz, Olumiant |
| Abbvie INC. | $162.37 | 2019-2023 | |
| Dermavant Sciences, INC. | $79.23 | 2023-2024 | Vtama |
| Pfizer INC. | $79.00 | 2019-2024 | |
| Janssen Biotech, INC. | $77.35 | 2022-2023 | Tremfya |
| Ucb, INC. | $75.43 | 2024 | Cimzia |
| Radius Health, INC. | $41.32 | 2023-2024 | Tymlos |
| Sun Pharmaceutical Industries INC. | $40.05 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.06 | 2019-2020 | |
| Coloplast Corp | $33.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.66 | 2025 | Entyvio |
| Dynavax Technologies Corporation | $26.04 | 2023 | Heplisav-B |
| Aurinia Pharma U.S., INC. | $22.49 | 2023 | Lupkynis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $21.71 | 2023 | |
| Galderma Laboratories, L.P. | $18.97 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $17.95 | 2023 | Dupixent |
| Botanix Sb INC | $16.94 | 2025 | Sofdra |
| Celgene Corporation | $15.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehran Nowfar-Rad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.